Scholarlink

Purpose <p>To investigate the efficacy of [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT for assessing viable tumours (VTs) after local regional treatment (LRT) in hepatocellular carcinoma (HCC) patients. The related imaging features of HCC after LRT are preliminarily discussed.</p> Methods <p>A cohort of 37 LRT patients with HCC (encompassing 51 lesions) was retrospectively included from a prospective parent study (ChiCTR2000039099), and sequential PET/CT using [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-04 was performed. The diagnostic accuracies of [<sup>68</sup>Ga]Ga-FAPI-04 and [<sup>18</sup>F]FDG PET/CT and multiphasic CT/MRI for detecting VTs after LRT were calculated and analysed. Pathological examination was considered the gold standard for VT diagnosis, and clinical follow-up was used as the reference standard. The SUVmax and tumour-to-background ratio (TBR) derived from [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT were calculated and compared. Moreover, the SUVmax, target-to-normal liver ratio (TNR) of VT, tumour necrosis (TN), benign rim (BR), and normal liver (NL) from different imaging modalities after LRT for HCC were compared.</p> Results <p>Both the sensitivity (96.0% [24/25] vs. 36.0% [9/25], <i>p</i> &lt; 0.001) and accuracy (94.1%, [48/51] vs. 68.6% [35/51], <i>p</i> = 0.004) of [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT for detecting VTs after LRT were greater than those of [<sup>18</sup>F]FDG PET/CT, whereas their specificities were comparable (92.3% [24/26] vs. 100% [26/26]). Notably, [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT had a greater SUVmax (9.80 vs. 3.60) and TBR (9.93 vs. 1.57) than [<sup>18</sup>F]FDG PET/CT in VT patients (all <i>p</i> &lt; 0.001). Furthermore, VT had a greater SUVmax and TNR than did TN, BR, and NL on [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT (all <i>p</i> &lt; 0.001) and exhibited morphologic nodular, mass-like, or irregular tracer uptake. Although no significant differences were observed for VT detection (all <i>p</i> &gt; 0.05), [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT and multiphasic CT/MRI complemented each other in some cases.</p> Conclusion <p>[<sup>68</sup>Ga]Ga-FAPI-04 PET/CT not only presented higher sensitivity and accuracy than [<sup>18</sup>F]FDG PET/CT for diagnosing VTs after LRT for HCC but also showed comparable diagnostic accuracy and complementary roles with multiphasic CT/MRI. Overall, [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT may play an essential role in surveillance after LRT for HCC.</p> Trial registration <p>Chinese Clinical Trial Registry ChiCTR2000039099. Registered 17 October 2020.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma

  • 期刊论文

  • 发表日期：

    2025年1月20日

查看全文
  • Dongling Zhu,
  • Shuang Song,
  • Sijuan Zou,
  • Dong Kuang,
  • Dongdong Wang,
  • Xiangde Min,
  • Zhaoyan Feng,
  • Yuankai Zhu,
  • Zhaoting Cheng,
  • Siyuan Cheng,
  • Jianyuan Zhou,
  • Ruping Pan,
  • Haojun Chen,
  • Xiaohua Zhu

摘要

Purpose

To investigate the efficacy of [68Ga]Ga-FAPI-04 PET/CT for assessing viable tumours (VTs) after local regional treatment (LRT) in hepatocellular carcinoma (HCC) patients. The related imaging features of HCC after LRT are preliminarily discussed.

Methods

A cohort of 37 LRT patients with HCC (encompassing 51 lesions) was retrospectively included from a prospective parent study (ChiCTR2000039099), and sequential PET/CT using [18F]FDG and [68Ga]Ga-FAPI-04 was performed. The diagnostic accuracies of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT and multiphasic CT/MRI for detecting VTs after LRT were calculated and analysed. Pathological examination was considered the gold standard for VT diagnosis, and clinical follow-up was used as the reference standard. The SUVmax and tumour-to-background ratio (TBR) derived from [18F]FDG and [68Ga]Ga-FAPI-04 PET/CT were calculated and compared. Moreover, the SUVmax, target-to-normal liver ratio (TNR) of VT, tumour necrosis (TN), benign rim (BR), and normal liver (NL) from different imaging modalities after LRT for HCC were compared.

Results

Both the sensitivity (96.0% [24/25] vs. 36.0% [9/25], p < 0.001) and accuracy (94.1%, [48/51] vs. 68.6% [35/51], p = 0.004) of [68Ga]Ga-FAPI-04 PET/CT for detecting VTs after LRT were greater than those of [18F]FDG PET/CT, whereas their specificities were comparable (92.3% [24/26] vs. 100% [26/26]). Notably, [68Ga]Ga-FAPI-04 PET/CT had a greater SUVmax (9.80 vs. 3.60) and TBR (9.93 vs. 1.57) than [18F]FDG PET/CT in VT patients (all p < 0.001). Furthermore, VT had a greater SUVmax and TNR than did TN, BR, and NL on [68Ga]Ga-FAPI-04 PET/CT (all p < 0.001) and exhibited morphologic nodular, mass-like, or irregular tracer uptake. Although no significant differences were observed for VT detection (all p > 0.05), [68Ga]Ga-FAPI-04 PET/CT and multiphasic CT/MRI complemented each other in some cases.

Conclusion

[68Ga]Ga-FAPI-04 PET/CT not only presented higher sensitivity and accuracy than [18F]FDG PET/CT for diagnosing VTs after LRT for HCC but also showed comparable diagnostic accuracy and complementary roles with multiphasic CT/MRI. Overall, [68Ga]Ga-FAPI-04 PET/CT may play an essential role in surveillance after LRT for HCC.

Trial registration

Chinese Clinical Trial Registry ChiCTR2000039099. Registered 17 October 2020.